Does acute phase protein α1-antitrypsin reduce the bacterial burden in mice by selective modulation of innate cell responses?
hAAT reduces the bacterial burden after infection. Since hAAT does not block bacterial growth in culture, its effects might rely on host immune cell modulation. These outcomes suggest that prolonged hAAT treatment in patients without hAAT deficiency is safe. Additionally, hAAT treatment may be considered a preemptive therapeutic measure for individuals who are at risk for bacterial infections.
We identified global promoter methylation profiling as being of relevance for subgrouping and prognostication of pediatric T-ALL.